Galapagos NV (GXEA) - Net Assets
Based on the latest financial reports, Galapagos NV (GXEA) has net assets worth €2.45 Billion EUR (≈ $2.86 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€3.51 Billion ≈ $4.11 Billion USD) and total liabilities (€1.06 Billion ≈ $1.25 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Galapagos NV asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €2.45 Billion |
| % of Total Assets | 69.68% |
| Annual Growth Rate | 18.23% |
| 5-Year Change | 8.49% |
| 10-Year Change | N/A |
| Growth Volatility | 44.48 |
Galapagos NV - Net Assets Trend (2016–2024)
This chart illustrates how Galapagos NV's net assets have evolved over time, based on quarterly financial data. Also explore GXEA current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Galapagos NV (2016–2024)
The table below shows the annual net assets of Galapagos NV from 2016 to 2024. For live valuation and market cap data, see GXEA market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €2.90 Billion ≈ $3.39 Billion |
+3.63% |
| 2023-12-31 | €2.80 Billion ≈ $3.27 Billion |
+10.67% |
| 2022-12-31 | €2.53 Billion ≈ $2.95 Billion |
-4.44% |
| 2021-12-31 | €2.64 Billion ≈ $3.09 Billion |
-1.01% |
| 2020-12-31 | €2.67 Billion ≈ $3.12 Billion |
-7.14% |
| 2019-12-31 | €2.88 Billion ≈ $3.36 Billion |
+136.83% |
| 2018-12-31 | €1.21 Billion ≈ $1.42 Billion |
+19.99% |
| 2017-12-31 | €1.01 Billion ≈ $1.18 Billion |
+33.38% |
| 2016-12-31 | €758.70 Million ≈ $887.00 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Galapagos NV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2203400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €3.03 Billion | 104.64% |
| Total Equity | €2.90 Billion | 100.00% |
Galapagos NV Competitors by Market Cap
The table below lists competitors of Galapagos NV ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tyra Biosciences Inc
NASDAQ:TYRA
|
$1.83 Billion |
|
Bikaji Foods International Limited
NSE:BIKAJI
|
$1.83 Billion |
|
Grupo Gigante S. A. B. de C. V
MX:GIGANTE
|
$1.83 Billion |
|
Ora Banda Mining Ltd
AU:OBM
|
$1.83 Billion |
|
Harmony Biosciences Holdings
NASDAQ:HRMY
|
$1.83 Billion |
|
Malaysian Pacific Industries
KLSE:3867
|
$1.83 Billion |
|
LTC Properties Inc
NYSE:LTC
|
$1.83 Billion |
|
Akr Corporindo Tbk
JK:AKRA
|
$1.83 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Galapagos NV's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,795,566,000 to 2,896,939,000, a change of 101,373,000 (3.6%).
- Net income of 74,082,000 contributed positively to equity growth.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €74.08 Million | +2.56% |
| Other Changes | €27.29 Million | +0.94% |
| Total Change | €- | 3.63% |
Book Value vs Market Value Analysis
This analysis compares Galapagos NV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.54x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.20x to 0.54x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €19.87 | €23.80 | x |
| 2018-12-31 | €22.29 | €23.80 | x |
| 2019-12-31 | €44.47 | €23.80 | x |
| 2020-12-31 | €40.82 | €23.80 | x |
| 2021-12-31 | €40.32 | €23.80 | x |
| 2022-12-31 | €38.37 | €23.80 | x |
| 2023-12-31 | €42.42 | €23.80 | x |
| 2024-12-31 | €43.96 | €23.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Galapagos NV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 26.88%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.43x
- Recent ROE (2.56%) is above the historical average (-1.71%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 7.12% | 41.70% | 0.12x | 1.43x | €-21.86 Million |
| 2017 | -11.43% | -91.04% | 0.10x | 1.27x | €-216.90 Million |
| 2018 | -2.41% | -10.13% | 0.20x | 1.19x | €-150.68 Million |
| 2019 | 5.21% | 17.73% | 0.14x | 2.11x | €-137.72 Million |
| 2020 | -11.44% | -63.89% | 0.08x | 2.14x | €-572.47 Million |
| 2021 | -3.91% | -21.29% | 0.09x | 1.96x | €-367.57 Million |
| 2022 | -8.63% | -43.14% | 0.11x | 1.87x | €-470.59 Million |
| 2023 | 7.57% | 88.31% | 0.06x | 1.56x | €-67.86 Million |
| 2024 | 2.56% | 26.88% | 0.07x | 1.43x | €-215.61 Million |
Industry Comparison
This section compares Galapagos NV's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $698,488,333
- Average return on equity (ROE) among peers: -63.13%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Galapagos NV (GXEA) | €2.45 Billion | 7.12% | 0.44x | $1.83 Billion |
| TIZIANA LIFE SCIENCES LTD (0RP) | $5.54 Million | -319.56% | 1.20x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $441.80 Million | 197.40% | 0.37x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-4.10 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $538.39 Million | -12.38% | 0.07x | $44.01 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $32.50 Million | -376.16% | 5.37x | $1.12 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $1.38 Billion | -51.05% | 0.17x | $2.05 Billion |
| BioNTech SE (22UA) | $493.49 Million | -36.28% | 0.62x | $23.24 Billion |
| Ascletis Pharma Inc (2VJ) | $2.54 Billion | -12.40% | 0.05x | $2.05 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.56 Billion | -20.91% | 0.36x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $-247.66K | 0.00% | 0.00x | $3.31 Million |
About Galapagos NV
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product c… Read more